Combining anti-TIGIT and anti-LAG-3 with conventional anti-PD-1/anti-PD-L1 therapies has been shown to improve median survival in non-small cell lung carcinoma and melanoma [25,30]. Here, TIGIT is linked to non-small cell lung carcinoma.